Zevra Therapeutics annual return on equity
2021
2022
2023
2024
2025
Zevra Therapeutics Return on Equity (ROE) Growth & History (ZVRA)
Zevra Therapeutics's return on equity was 85.66% for fiscal 2025.
View full Zevra Therapeutics company overviewZevra Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 85.66% | +293.50 pp |
| 2024 | 2024-12-31 | −207.84% | −140.61 pp |
| 2023 | 2023-12-31 | −67.23% | −36.94 pp |
| 2022 | 2022-12-31 | −30.29% | +18.25 pp |
| 2021 | 2021-12-31 | −48.54% | — |
Zevra Therapeutics quarterly return on equity
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 4.13% | −90.28 pp |
| Q1 2026 | 2026-03-31 | 21.02% | +28.70 pp |
| Q4 2025 | 2025-12-31 | 8.45% | +73.77 pp |
| Q3 2025 | 2025-09-30 | −0.43% | +64.55 pp |
| Q2 2025 | 2025-06-30 | 94.41% | +143.43 pp |
| Q1 2025 | 2025-03-31 | −7.68% | +22.35 pp |
| Q4 2024 | 2024-12-31 | −65.31% | −33.07 pp |
| Q3 2024 | 2024-09-30 | −64.99% | −47.77 pp |
| Q2 2024 | 2024-06-30 | −49.02% | −44.66 pp |
| Q1 2024 | 2024-03-31 | −30.04% | −10.37 pp |
| Q4 2023 | 2023-12-31 | −32.24% | −39.05 pp |
| Q3 2023 | 2023-09-30 | −17.22% | −10.37 pp |
| Q2 2023 | 2023-06-30 | −4.36% | +17.43 pp |
| Q1 2023 | 2023-03-31 | −19.67% | −18.00 pp |
| Q4 2022 | 2022-12-31 | 6.81% | +9.12 pp |
| Q3 2022 | 2022-09-30 | −6.85% | −5.51 pp |
| Q2 2022 | 2022-06-30 | −21.78% | −27.56 pp |
| Q1 2022 | 2022-03-31 | −1.67% | +113.76 pp |
| Q4 2021 | 2021-12-31 | −2.32% | — |
| Q3 2021 | 2021-09-30 | −1.34% | — |
| Q2 2021 | 2021-06-30 | 5.77% | — |
| Q1 2021 | 2021-03-31 | −115.43% | — |
Zevra Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Zevra Therapeutics's return on equity increased from −48.54% to 85.66%, a change of +134.20 percentage points. The latest reported quarter, Q2 2026, shows 4.13%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Zevra Therapeutics source filings ↗